Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budiodarone dose-escalation study in non-permanent atrial fibrillation
2025-523860-19-00Phase 3Authorised
- Sponsor
- XYRA LLC
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of budiodarone in Atrial fibrillation (AFib), sponsored by XYRA LLC. Primary endpoints: Safety and Primary efficacy. Planned start Jul 2026; status: authorised.
02
Drugs
budiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-523860-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523860-19-00.